CYTK
$61.70-1.25 (-1.99%)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States.
Recent News
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes
Why new MYQORZO data is back in focus for Cytokinetics (CYTK) Cytokinetics (CYTK) is back on investors’ radar after fresh MYQORZO data at the American College of Cardiology meeting highlighted exercise capacity benefits, a consistent safety profile, and flexibility around temporary treatment interruptions. See our latest analysis for Cytokinetics. At a share price of US$60.83, Cytokinetics has seen a 1-day share price return of 1.28% and a 30-day share price return decline of 8.20%. However,...
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomy